Loading...
•
Sep 30
Geron Q3 2025 Earnings Report
Geron Corporation reported its third quarter 2025 financial results, highlighting strong RYTELO® net product revenue and advancements in its clinical pipeline.
Key Takeaways
Geron Corporation delivered a strong third quarter in 2025, driven by significant RYTELO® net product revenue of $47.2 million. The company also completed enrollment in its Phase 3 IMpactMF clinical trial and strengthened its leadership team, positioning itself for continued growth and commercial execution.
Achieved $47.2 million in RYTELO® net product revenue in Q3 2025, a substantial increase from the previous year.
Completed enrollment of 320 patients in the IMpactMF Phase 3 clinical trial for relapsed/refractory myelofibrosis.
Strengthened the leadership team with the appointment of a Chief Commercial Officer and additional key executives to drive strategic priorities.
Reported a net loss of $18.4 million, or $0.03 per share, a notable improvement compared to $26.4 million, or $0.04 per share, in Q3 2024.
Geron
Geron
Geron Revenue by Segment
Revenue by Segment
Product Revenue, Net Revenue
CapyFin.comRoyalties Revenue
CapyFin.com Forward Guidance
For fiscal year 2025, Geron Corporation expects total operating expenses to be between $250 million and $260 million, a reduction from previous guidance. The company believes its existing financial resources, combined with anticipated RYTELO sales, will be sufficient to fund projected operating requirements for the foreseeable future.
Positive Outlook
- Reduced fiscal year 2025 total operating expense guidance to $250 million - $260 million, down from $270 million - $285 million.
- Existing cash, cash equivalents, and marketable securities, along with anticipated RYTELO sales, are expected to fund projected operating requirements for the foreseeable future.
- Expects IMpactMF interim analysis readout for overall survival in the second half of 2026.
- Focus on strengthening commercial execution and increasing RYTELO sales in the U.S.
- Plans to present meaningful data at ASH and enhance partnerships with the MDS community.
Challenges Ahead
- Demand for RYTELO was down 3% quarter-over-quarter, indicating a need to elevate brand awareness and clinical value communications.
- Research and development expenses are expected to increase in the remaining quarter of 2025 over 2024 levels.
- The IMpactMF final analysis is not expected until the second half of 2028, indicating a long development timeline.
- The company acknowledges 'work ahead of us to fully maximize the value of this therapy and ensure RYTELO reaches more patients'.
- No specific negative financial guidance was provided beyond the operating expense range.